<DOC>
	<DOCNO>NCT01748838</DOCNO>
	<brief_summary>The purpose study assess safety tolerability CTX-4430 capsule take orally daily normal healthy volunteer . CTX-4430 develop treat lung inflammation occur cystic fibrosis ( CF ) . This study include two-parts : Part 1 ass single dosing ; Part 2 assess repeat dose 14 day . Each part include several dosage . During single-dose part study , follow 14-day washout period , two cohort assess potential effect tolerability feed time dosing . For part study , blood sample collect PK assay validation .</brief_summary>
	<brief_title>Phase 1 Study Assessing Safety Tolerability CTX-4430</brief_title>
	<detailed_description />
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Pneumonia</mesh_term>
	<mesh_term>Mannitol</mesh_term>
	<criteria>Male female , 18 55 year age Medically healthy Body mass index ≥ 18.0 ≤ 29.9 Nontobacco/nicotinecontaining product user 6 month prior first study drug administration Negative urine drug/alcohol screen prior Day 1 Voluntary consent Male agree sexually abstinent use condom engage sexual activity completion Females childbearing potential must either sexually inactive 14 day prior first study drug administration remain 30 day follow final dosing study drug , use one follow method birth control time specify : Intrauterine device place least 3 month prior Double barrier method least 14 day prior Male partner surgical sterile least 6 month prior first study drug administration sole sexual partner female Adequate hormonal contraception.Female subject become sexually active course study must use double barrier method start sexual activity 30 day follow final dosing Females nonchildbearing potential undergone one follow sterilization procedure least 6 month prior first study drug administration : Essure® sterilization use barrier method throughout study bilateral tubal ligation barrier method throughout study hysterectomy bilateral oophorectomy postmenopausal amenorrhea least 1 year prior first study drug administration follicle stimulate hormone serum level ≥40 mIU/mL Subject Forced Expiratory Volume ≥80 % predict screen Subject rest oxygen saturation &gt; 92 % room air Positive test human immunodeficiency virus , hepatitis B surface antigen , hepatitis C antibody Subject febrile stage screen predose History presence alcoholism drug abuse within 2 year prior first study drug administration Hypersensitivity idiosyncratic reaction compound related CTX4430 . Use overthecounter medication , ( include herbal product vitamin supplement ) , within 7 day prior Day 1 . Use nonsteroidal antiinflammatory drug , aspirin , antirheumatic drug , leukotriene receptor antagonist , leukotriene enzyme inhibitor within 14 day prior first study drug administration 5 halflives , whichever longer . Administration use oral , inhaled , intranasal , parenteral , &gt; 1 % topical glucocorticoid within 6 month prior Day 1 Use significant inhibitor substrates OAT3 , OCT2 and/or OATP P1/B1 within 30 day prior first study drug administration Blood donation significant blood loss within 60 day prior first study drug administration Plasma donation within 7 day prior first study drug administration . Participation another clinical trial within 30 day prior first study drug administration Females pregnant lactate Clinically relevant surgery within past three month prior first drug administration Personal family history prolong QT syndrome ; QTc interval &gt; 430 msec ( male ) &gt; 450 msec ( female ) Sitting blood pressure le 90/40 mmHg great 140/90 mmHg Pulse high 100 b.p.m . Regular alcohol consumption male &gt; 21 unit per week female &gt; 14 unit per week Failure satisfy PI fitness participate reason Active infection History seizure History presence clinically significant cardiovascular , pulmonary , hepatic , renal , haematological , gastrointestinal , endocrine , immunologic , dermatologic , neurological , psychiatric disease Use prescription medication within 14 day prior Day 1 Acute illness within 30 day prior Day 1</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>September 2013</verification_date>
</DOC>